Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 7/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | BCL6 | P41182 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 6/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | ITK | Q08881 | 2/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1027670 | 0.88 | BCL6 (0.38) | CTSCBTKBCL6EGFRJAK3 | |
| SCHEMBL1028340 | 0.87 | CTSC (0.42) | CTSCBTKBCL6EGFRBRD4 | |
| SCHEMBL1026422 | 0.87 | BCL6 (0.38) | CTSCBTKBCL6EGFRMET | |
| SCHEMBL1025086 | 0.86 | BCL6 (0.38) | CTSCBTKBCL6EGFRJAK3 | |
| SCHEMBL1025568 | 0.85 | CTSC (0.42) | CTSCBTKEGFRSYKJAK3 | |
| SCHEMBL13623112 | 0.84 | EGFR (0.46) | CTSCBTKBCL6EGFRBRD4 | |
| SCHEMBL1026395 | 0.79 | BCL6 (0.40) | CTSCBTKBCL6EGFRJAK3 | |
| SCHEMBL1026332 | 0.78 | BCL6 (0.41) | CTSCKDRBCL6EGFRBRD4 | |
| SCHEMBL1026721 | 0.78 | JAK3 (0.42) | CTSCBCL6JAK3 | |
| SCHEMBL1025784 | 0.77 | TSHR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |